RxDoctor Payments Data

Frank Mongillo, MD

Internal Medicine · New Haven, CTNPI 1811917289

Payments from drug & device makers

$12,580in general payments, 2019–2025

Across 165 payments — averaging $76.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$8K
  • GSK$783
  • Novo Nordisk$671
  • Amgen$418
  • Bayer$345
  • AbbVie$299
  • plus $2K from 17 others

What the payments were for

  • Speaking & faculty fees$6,45051%
  • Travel & lodging$1,0378%
  • Food & beverage$4,99340%
  • Education$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,580 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$33,845
Medicare patients
65
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$106,631
JanuviaSitagliptin Phosphate34$43,054
SuboxoneBuprenorphine Hcl/Naloxone Hcl42$34,359
FarxigaDapagliflozin Propanediol32$34,075
MounjaroTirzepatide23$28,652
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl131$21,103
RexultiBrexpiprazole11$15,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,079
EliquisApixaban12$13,738
Tresiba Flextouch U-200Insulin Degludec16$9,562
Midodrine Hcl17$2,446
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen99$2,279
FenofibrateFenofibrate Nanocrystallized44$2,278
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$2,125
Atorvastatin Calcium323$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$671$106,631105 claims
MerckJanuvia$125$43,05434 claims
Indivior Inc.Suboxone$8,117$34,35942 claims
AstraZenecaFarxiga$282$34,07532 claims
Lilly USA, LLCMounjaro$238$28,65223 claims
Otsuka America Pharmaceutical, Inc.Rexulti$30$15,90711 claims
GSKTrelegy Ellipta$783$15,07924 claims
PfizerEliquis$39$13,73812 claims
AbbVieSynthroid$299$1,54211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →